BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

C-CAMP partners with Assam government to strengthen public healthcare

12 December 2023 | News

C-CAMP has implemented 3 key healthcare programmes in Assam



Building on the last three years' effort of strengthening Assam's public health system through world class, indigenous innovation, Bengaluru-based Centre for Cellular and Molecular Platforms (C-CAMP) has signed a Memorandum of Understanding (MoU) with the Medical Education & Research Department (ME&RD), Government of Assam towards focused innovation driven programmes for improving technology adoption by healthcare practitioners, infrastructure upgrades and capacity-building.

The MoU was signed at Dispur, Guwahati by C-CAMP Director and CEO, Dr Taslimarif Saiyed and Siddharth Singh, IAS, Commissioner and Secretary, Medical Education and Research Department on behalf of the Govt of Assam in presence of Health Minister, Keshab Mahanta.

In Assam, C-CAMP has implemented 3 key healthcare programmes with funding support from national and international philanthropic organisations targeting important areas such as maternal and child healthcare, hospital infrastructure facility and immunisation including COVID-19 drives.

307 units of limited-resource, respiratory support technology have been implemented, to cover 100% infrastructure requirement for newborn and paediatric critical care to all district hospitals and medical colleges in Assam.

A second project deployed 200 electronic temperature-regulated active vaccine carriers across 12 districts to strengthen last mile cold chain facilities for routine immunisation & COVID-19 vaccination.

C-CAMP has also set up an oxygen-supported 54 bedded augmented hospital facility at Uluoni CHC under Simonabasti BPHC, Nagaon.

The immediate action point for the collaboration will be to intensify efforts in the above projects and align more emerging solutions with needs on the ground. In the immediate pipeline is a project to improve early screening and detection in Retinopathy of Prematurity, a common eye disease affecting premature babies and newborns through context-specific innovative health solutions.